Multicenter, Phase II Study of Chemotherapy in Combination With Trastuzumab in Patients of Pretreated, HER2 Positive, Relapse or Metastatic Carcinoma of Digestive System
Latest Information Update: 01 Mar 2022
Price :
$35 *
At a glance
- Drugs Trastuzumab (Primary) ; Capecitabine; Fluorouracil; Irinotecan
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Digestive system neoplasms; Gastrointestinal cancer; Oesophageal cancer; Rectal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 22 Jan 2022 Results (n=21) assessing antitumor activity of trastuzumab plus irinotecan in pretreated patients with HER2-postive unresectable metastatic CRC and explore biomarkers for response and resistance to this treatment presented at the 2022 Gastrointestinal Cancers Symposium
- 17 Jul 2019 Planned number of patients changed from 75 to 100.
- 17 Jul 2019 Status changed from not yet recruiting to recruiting.